Circulating MicroRNA-21 is Downregulated in Patients with Metabolic Syndrome

Biomed Environ Sci. 2016 May;29(5):385-9. doi: 10.3967/bes2016.050.

Abstract

The microRNA-21 (miR-21) is known to play a major role in cancer progression; however, its function in the cardiovascular system appears to be even more complex and conflicting. To characterize miR-21 expression in the plasma of individuals with or without metabolic syndrome (MetS), 58 MetS cases and 96 non-MetS controls were investigated. Expression levels of miR-21 were significantly decreased in the circulation of MetS subjects (OR=0.52, 95% CI: 0.29-0.92) compared with that of non-MetS subjects. Body mass index (BMI) and the number of MetS components had a negative correlation with the level of miR-21, whereas age was inversely related to the level of miR-21. No significant difference was detected in miR-21 levels between the sexes (P=0.056). MiR-21 might be a negative regulating factor in MetS.

MeSH terms

  • Adult
  • Aged
  • Down-Regulation*
  • Female
  • Humans
  • Male
  • Metabolic Syndrome / blood
  • Metabolic Syndrome / etiology
  • Metabolic Syndrome / genetics*
  • MicroRNAs / blood
  • MicroRNAs / genetics*
  • MicroRNAs / metabolism
  • Middle Aged
  • Real-Time Polymerase Chain Reaction
  • Reverse Transcriptase Polymerase Chain Reaction
  • Risk Factors

Substances

  • MIRN21 microRNA, human
  • MicroRNAs